p21CIP/WAF1 saRNA inhibits proliferative vitreoretinopathy in a rabbit model

Area of Science:

• Ophthalmology
• Molecular Biology
• Regenerative Medicine

Background:

• Proliferative vitreoretinopathy (PVR) is a severe complication following retinal detachment surgery.
• PVR involves the proliferation and migration of retinal pigment epithelial (RPE) cells, leading to scar tissue formation and vision loss.
• Current treatments for PVR have limited efficacy, necessitating novel therapeutic strategies.

Purpose of the Study:

• To evaluate the therapeutic potential of a p21-inducing small interfering RNA (siRNA) for treating PVR.
• To investigate the effects of p21 siRNA on RPE cell proliferation, migration, and cell cycle progression.
• To assess the in vivo efficacy and pharmacokinetics of a cholesterol-conjugated p21 siRNA in a rabbit PVR model.

Main Methods:

• Chemically modified p21 siRNA (RAG1-40-53) was tested in cultured human RPE cells.
• siRNA effects on p21 induction, cell proliferation, migration, and cell cycle were analyzed.
• Cholesterol-conjugated RAG1-40-53 was administered intravitreally in a rabbit PVR model to assess pharmacokinetics, pharmacodynamics, and therapeutic effects.

Main Results:

• RAG1-40-53 significantly induced p21 expression in RPE cells.
• The siRNA inhibited RPE cell proliferation and TGF-β1-induced migration.
• Intravitreal injection of cholesterol-conjugated RAG1-40-53 demonstrated sustained intraocular presence and prevented PVR progression in rabbits.

Conclusions:

• p21 siRNA demonstrates significant anti-proliferative and anti-migratory effects on RPE cells.
• This p21 siRNA represents a promising novel therapeutic agent for PVR.
• Further investigation is warranted to explore its clinical application in managing PVR.